Inovio plans to submit a bla for ino-3107 as a potential treatment for rrp in second half of 2024 under accelerated approval program

Company will request rolling submission and priority review of its biological license application (bla) by u.s. food and drug administration (fda) to expedite review process accelerating commercialization efforts to be prepared to launch ino-3107 in 2025 plymouth meeting, pa. , jan. 3, 2024 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced plans to submit a bla for ino-3107 as a potential treatment for recurrent respiratory papillomatosis (rrp) in the second half of 2024.
INO Ratings Summary
INO Quant Ranking